| Outline of Final Research Achievements |
The prognosis of bone and soft tissue sarcomas are still extremely poor. As sarcomas is a rare cancer, the development of novel treatments has been delayed due to the limited amount of data and the associated negative efforts. In recent years, precision medicine based on a cancer clinical sequence, which uses a next-generation sequencer has been developed in across all cancer types. Additionally, in Japan, cancer gene panel tests were recently approved in government health care.
In this study, we mainly performed genome-based profiling of bone soft tissue sarcomas using MSK-IMPAC, which is a cancer clinical sequence and approved by FDA. These studies elucidated the frequency of potential actionable gene alteration based on OncoKB in each bone and soft tissue sarcomas as well as identified novel therapeutic targets and strategies based on gene profiling in osteosarcoma.
|
